V8 Peptides — Engineered Performance
Research Library
KPV Nanoparticle Delivery Systems: A Research Review
KPVGuide

KPV Nanoparticle Delivery Systems: A Research Review

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How was KPV delivered in nanoparticle studies? Two published preclinical systems loaded KPV into polymeric nanoparticles (about 400 nm, and about 272 nm with a hyaluronic acid coating) inside chitosan/alginate hydrogels for colonic release. One reports similar efficacy at a 12,000-fold lower KPV concentration than free KPV in a mouse DSS model. For laboratory research use only.

A tripeptide should be an easy molecule to deliver, and yet the best-known KPV delivery work is about packaging it into nanoparticles. The reason is the gut. A peptide given by mouth meets stomach acid, proteases and a long, variable intestinal transit, so researchers asked whether a carrier could bring KPV to the inflamed colon in a protected form. This article explains how two published nanoparticle-and-hydrogel systems were built, what the authors measured and what a reader should keep in mind about carrier research. It is a description of published preclinical engineering, not a how-to. For laboratory research use only; not for human consumption.

The KPV research vials page offers free KPV as 5 mg and 10 mg lyophilized vials at ≥98% HPLC purity; it does not offer nanoparticle formulations, and nothing here describes making them for any use outside a laboratory. Background on the peptide is in the KPV research overview, and the model context is in the article on murine colitis models.

The problem the carriers were designed to address

The first KPV colitis work gave the peptide in the drinking water of mice and linked its effect to uptake through PepT1, a transporter that handles di- and tripeptides [3, 4]. PepT1 is normally found in the small intestine and absent in the colon, but it has been reported to appear in colonic epithelium in chronic inflammatory bowel disease tissue [5]. A free peptide, however, has to survive the upper gut to reach the colon at all, and it is cleared quickly. The nanoparticle work asks whether wrapping KPV in a particle, and the particle in a hydrogel that releases it in the colon, can deliver it where inflammation is and in smaller amounts.

System one: nanoparticles inside an alginate–chitosan hydrogel

In the first system, the authors synthesized nanoparticles by a double-emulsion and solvent-evaporation process, loading KPV during the first emulsion. The particles, about 400 nm in diameter, did not affect cell viability or barrier function in cultured intestinal cells. To aim them at the colon, the loaded particles were encapsulated in a polysaccharide hydrogel made of alginate and chitosan. A swelling study showed that the hydrogel collapsed in the colon, after which the particles released KPV on or near colonocytes. In Caco2-BBE cells, the particle preparation reduced responses to lipopolysaccharide in a dose-dependent manner, and in mice given DSS followed by the particle-in-hydrogel preparation, inflammatory and histologic parameters were protected relative to DSS alone. The authors report that KPV could be delivered at a concentration 12,000-fold lower than free KPV with similar efficacy [1].

System two: hyaluronic-acid-functionalized particles

The second system added a targeting layer. KPV was loaded into hyaluronic acid (HA)-functionalized polymeric nanoparticles with a size of about 272 nm and a slightly negative zeta potential of about −5.3 mV. These particles mediated delivery to colonic epithelial cells and macrophages, appeared nontoxic and biocompatible with intestinal cells, and, according to the authors, combined acceleration of mucosal healing with reduced inflammation. When the HA-particles were encapsulated in a chitosan/alginate hydrogel and given orally to mice, they were reported to prevent mucosal damage and reduce TNF-α more strongly than a KPV-particle/hydrogel system without HA [2]. The comparison is within one paper and one model.

FeatureLaroui et al. [1]Xiao et al. [2]
CarrierPolymeric nanoparticles in alginate–chitosan hydrogelHA-functionalized polymeric nanoparticles in chitosan/alginate hydrogel
Particle sizeAbout 400 nmAbout 272 nm; zeta potential about −5.3 mV
Targeting ideaHydrogel collapse in the colon, then particle release near colonocytesHA-mediated targeting of colonic epithelial cells and macrophages
Cell workCaco2-BBE cells, LPS challengeUptake in colonic epithelial cells and macrophages; biocompatibility
Animal modelDSS colitis, miceUlcerative-colitis mouse model
Headline claimSimilar efficacy at a 12,000-fold lower KPV concentration than free KPVStronger effect than the non-HA particle system

What the measurements in carrier papers mean

Delivery papers report a set of material attributes that are unfamiliar to peptide-only labs. Particle size influences cell uptake and tissue penetration. Zeta potential is the surface charge in suspension and affects stability and interaction with mucus and cells. Loading and release describe how much peptide is in the particle and how quickly it leaves. Swelling or collapse of a hydrogel describes when the carrier opens. Each is a property of the preparation, not of KPV. A lab that wanted to reproduce a carrier result would need to reproduce those properties, and that is a materials-science task: the peptide identity and purity are necessary but not sufficient.

AttributeWhat it describesWhy it can change a result
Particle diameterSize of the carrier, reported as about 400 nm and about 272 nm in the two systemsAffects uptake by cells and penetration into tissue
Zeta potentialSurface charge in suspensionAffects colloidal stability and contact with mucus and cell membranes
LoadingPeptide amount per amount of carrierSets the real concentration delivered
Release profileRate at which peptide leaves the carrierDetermines timing of exposure
Hydrogel behaviorSwelling or collapse in a given segment of gutDetermines where the particles are set free [1]

Two peptide-side points still matter. First, the amount of KPV in the particle has to be determined by an analytical method, and the loaded amount is what the dose-comparison claims rest on. Second, the peptide has to survive the encapsulation chemistry, which in the first system included an emulsion and solvent-evaporation step [1]. Forced-degradation approaches are the standard way to learn what a peptide tolerates [7], and peptides can be lost to surfaces during processing [6].

Interpreting the 12,000-fold claim

The 12,000-fold figure is striking, and it is easy to read too much into it. It compares the concentration of KPV required in the particle preparation with that of KPV in free solution, in one mouse colitis model and with one set of readouts [1]. It does not state a universal potency ratio, it does not address other models, and it describes delivered concentration under the authors' conditions. The more cautious reading is that localized, protected delivery appears to change the concentration needed for a protective readout in that model. For a sense of the free-peptide baseline, see the original oral-delivery work [3] and a second, independent colitis study [8].

Questions to ask of any peptide-carrier paper

  1. Is there a free-peptide arm at the same concentration as the carrier arm, and a blank-carrier arm without peptide? Without both, the carrier's contribution cannot be separated from the peptide's.
  2. How was loading measured, and what was the batch-to-batch variation?
  3. What is the release profile at relevant pH values and time points?
  4. Were carrier components themselves tested for effects in the assay? Chitosan, alginate and hyaluronic acid are bioactive materials in some systems.
  5. Were the readouts blinded, and was the same model used for all arms?

A blank-carrier control matters especially in a system in which a polysaccharide hydrogel is part of the preparation. The reports above describe comparison arms that include particles alone or particles without targeting, and the full texts should be checked for exact controls.

What this means for a lab using free KPV

For a laboratory working with a free-peptide reagent, the carrier literature is context, not protocol. It indicates why studies of oral or colonic KPV use concentrations that cannot be compared with those from cultured-cell work, and it warns that free-solution results may underestimate or overestimate what a localized delivery format would show. When citing a cell-culture concentration, say so; when citing an animal study, state whether the peptide was free or carried. The arithmetic for any free-peptide stock is a formula (concentration equals mass divided by diluent volume) handled by the reconstitution calculator, and general storage guidance for the reagent is in storing research peptides. For the question of identity and purity of the peptide itself, see KPV purity testing, how to read a COA, understanding HPLC purity and the COA page; for the uptake route and its limits, see KPV and PepT1 uptake background; for the parent hormone, see KPV vs α-MSH; for the broader literature map, see the article on reading the KPV literature.

Frequently asked questions

Why was KPV loaded into nanoparticles?

To deliver it to the colon in a protected form. Published work asked whether a carrier could bring KPV to inflamed colon tissue at a lower concentration than free KPV.

What are the two published systems?

Polymeric nanoparticles encapsulated in an alginate–chitosan hydrogel, and hyaluronic-acid-functionalized nanoparticles encapsulated in a chitosan/alginate hydrogel.

How large were the particles?

About 400 nm in the first system and about 272 nm, with a zeta potential near −5.3 mV, in the second.

What does the 12,000-fold figure mean?

One study reports similar efficacy at a KPV concentration 12,000-fold lower than free KPV in a DSS colitis model. It is a single-model finding.

Does V8 sell KPV nanoparticles?

No. The KPV product is a free lyophilized peptide in 5 mg and 10 mg vials supplied for laboratory research.

What is zeta potential?

The surface charge of a particle in suspension, which influences stability and interactions with cells and mucus.

What is the role of the hydrogel?

In the published work, the hydrogel collapsed in the colon and released the particles there, aiming delivery to that site.

Why does a blank-carrier control matter?

The carrier materials can affect cells, so a particle without KPV is needed to separate carrier effects from peptide effects.

Do these results apply outside mouse models?

They are preclinical results in cell lines and mice and do not extend beyond them.

Where is the free-peptide background?

In the KPV research overview and the article on published study parameters.

Related reading: KPV and NF-κB Signaling: Evidence by Pathway Step, KPV and the PepT1 Transporter: Uptake Evidence, KPV Peptide Explained: Sequence, Structure and Pathways.

References

  1. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-Loaded Nanoparticles Targeted to the Colon With Polysaccharide Hydrogel Reduce Colitis in a Mouse Model. Gastroenterology. 2010;138(3):843-853.e2. doi:10.1053/j.gastro.2009.11.003
  2. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628-1640. doi:10.1016/j.ymthe.2016.11.020
  3. Dalmasso G, Charrier–Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
  4. Daniel H. Molecular and Integrative Physiology of Intestinal Peptide Transport. Annu. Rev. Physiol.. 2004;66(1):361-384. doi:10.1146/annurev.physiol.66.032102.144149
  5. Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, Liu X, et al. Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: Transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology. 2001;120(7):1666-1679. doi:10.1053/gast.2001.24845
  6. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
  7. Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler Hc, Jiskoot W. Forced Degradation of Therapeutic Proteins. Journal of Pharmaceutical Sciences. 2012;101(3):895-913. doi:10.1002/jps.22812
  8. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. doi:10.1002/ibd.20334

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.